Tiziana Life Sciences PLC Appointment of Chief Medical Officer (4627L)
January 13 2021 - 2:00AM
UK Regulatory
TIDMTILS
RNS Number : 4627L
Tiziana Life Sciences PLC
13 January 2021
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as
Chief Medical Officer
New York/London, 13 January 2021 - Tiziana Life Sciences plc
(Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a
biotechnology company focused on innovative therapeutics for
oncology, inflammation, and infectious diseases, announces the
appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical
Officer.
Dr Graham is a medicines development expert and Infectious
Diseases Epidemiologist with global Biotech and Pharma R&D
experience in Phase I-IV therapeutics as well as in-vivo &
in-vitro diagnostics, across many modalities. He has in depth
Global Development Expertise (e.g. Virology, Respiratory,
Dermatology, Allergy, & Rheumatology) in early & late stage
Clinical Development and in Medical Affairs, with a strong track
record for Developing and Accelerating Phase I-IV programs.
Multiple IND's, NDA/BLA filings and/or defense and multiple
successful launches.
From 2010 to 2020, Dr Graham was VP of Strategic Program
Direction, Immunology and Inflammation at Regeneron
Pharmaceuticals, Inc., where he managed and oversaw a large portion
of the Regeneron pipeline portfolio including leading the
immunology and inflammation antibody products across all stages of
development from preclinical to post-launch. He was instrumental in
the development of DUPIXENT (dupilumab), a blockbuster monoclonal
antibody, from Phase 1 through its initial launch for atopic
dermatitis, as well as expanding its development into asthma,
sinusitis, and eight other indications. During his tenure at
Regeneron, Dr. Graham also led the product development for KEVZARA
(sarilumab), an IL-6R antibody for rheumatoid arthritis, and
REGN3500, an anti-IL33 antibody for asthma and COPD. As part of
this role he built innovative, high-performing development teams
and managed the Regeneron's regulatory filings, interactions with
regulatory agencies, product launches, and business development and
licensing activities across its product portfolio.
Prior to Regeneron, Dr. Graham served as Senior Vice President,
Program and Portfolio Management at Vertex, where he oversaw the
team of program leaders and managers across the portfolio from
Phase 1 through launch, including Telaprevir for hepatitis C (HCV),
and two innovative product candidates for cystic fibrosis which are
now on the market. Previously, he held roles as CMO at Trimeris
Inc. and XTL Biopharmaceuticals and worked in HIV Medical Affairs
at Glaxo Welcome. Earlier in his career, Dr. Graham was an
Associate Professor of Medicine and Epidemiology at John Hopkins
University, School of Hygiene and Public Health. He is the author
of five chapters and books and more than 140 peer-reviewed journal
articles. Dr. Graham earned an M.D., M.B.B.S., and M.P.H. from the
University of Adelaide in Australia.
Dr. Graham stated: "I am excited to join Tiziana to help develop
its unique monoclonal antibody platform for autoimmune diseases.
Tiziana's ability to deliver antibody immunotherapeutics via oral
and nasal routes is a potential game-changer for patients and
physicians alike".
Kunwar Shailubhai, CEO of Tiziana said: "We are very excited
about Dr. Graham's addition to the Tiziana team. Dr Graham's
invaluable experience at Regeneron and Vertex in different
disciplines is a great fit for the Tiziana pipeline."
"We are delighted to have Dr. Graham join the Tiziana team. His
knowledge and experience at Regeneron in developing blockbuster
monoclonal antibody drugs such as Dupixent will be invaluable in
developing Foralumab and our anti IL-6Drug, TZLS-501", said
Chairman and Founder Gabriele Cerrone
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
About Tiziana Life Sciences
Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA &
UK AIMS: TILS) biotechnology company that focuses on the discovery
and development of novel molecules to treat human diseases in
oncology, inflammation and infectious diseases. In addition to
milciclib, the Company will be shortly initiating Phase 2 studies
with orally administered Foralumab for Crohn's Disease and nasally
administered Foralumab for progressive multiple sclerosis.
Foralumab is the only fully human anti-CD3 monoclonal antibody
(mAb) in clinical development in the world. This Phase 2 compound
has potential application in a wide range of autoimmune and
inflammatory diseases, such as Crohn's Disease, multiple sclerosis,
type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis
and rheumatoid arthritis, where modulation of a T-cell response is
desirable. The company is accelerating development of
anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal
antibody for treatment of IL6-induced inflammation, especially for
treatment of COVID-19 patients.
For further enquiries:
United Kingdom:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
Cairn Financial Advisers LLP (Nominated adviser)
Liam Murray / Jo Turner +44 (0)20 7213 0880
Optiva Securities Limited (Broker)
Robert Emmet
United States:
Investors:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
dave@redchip.com +44 (0)20 3981 4173
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBRGDBCUBDGBD
(END) Dow Jones Newswires
January 13, 2021 02:00 ET (07:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Apr 2024 to May 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From May 2023 to May 2024